newsfilter
← Latest News
Business Wire·

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

- Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity - Topline data readout planned for early 2026 Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a